Amgen has gained a European marketing authorization for its biosimilar version of Abbvie’s anti-inflammatory drug adalimumab (Humira), making it the first European license for a biosimilar to adalimumab. Amgen’s product will be called biosimilar adalimumab (Amgevita).
Biosimilar adalimumab is approved for the following inflammatory conditions in adults:
It is also approved for the following pediatric conditions:
The approval comes from results of 2 phase 3 studies conducted in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis patients, each of which met their primary endpoint with no clinically meaningful differences to adalimumab, including safety and immunogenicity data.
Approval from the European Commission (EC) means Amgen can now market the drug across 28 countries across Europe. Other European Economic Area member nations, including Norway, Iceland and Liechtenstein, will take corresponding decisions based on the EC decision.
Called adalimumab-atto (Amjevita) in the United States, Amgen gained FDA approval in September 2016. However, pending legal issues have prevented market launch.
Global sales of Humira crossed $16 billion in 2016.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.